Lupkynis (voclosporin) / Aurinia Pharma 
Welcome,         Profile    Billing    Logout  
 19 Diseases   4 Trials   4 Trials   711 News 


«123456789»
  • ||||||||||  Benlysta (belimumab) / GSK, Luveniq (voclosporin) / Aurinia Pharma, Otsuka, anifrolumab (MEDI-546) / AstraZeneca
    Review, Journal:  One year in review 2021: systemic lupus erythematosus. (Pubmed Central) -  Apr 13, 2021   
    We will then present new treatment options (with a special focus on belimumab, anifrolumab, tacrolimus, voclosporin and EULAR/ERA-EDTA recommendations for the management of LN) and treat-to-target strategy. Lastly, we will concentrate on some of the aspects that influence patients' disease perception and quality of life.
  • ||||||||||  Luveniq (voclosporin) / Aurinia Pharma, Otsuka
    [VIRTUAL] VOCLOSPORIN INCREASES RENAL RESPONSE AT COMMONLY USED UPCR THRESHOLDS IN PATIENTS WITH LUPUS NEPHRITIS (Hall New York) -  Mar 19, 2021 - Abstract #ERAEDTA2021ERA_EDTA_559;    
    Participants treated with voclosporin in addition to MMF and low-dose glucocorticoids achieved statistically significantly increased renal response rates regardless of the level of UPCR used, including at an even more stringent ≤0.3 mg/mg target. This analysis further supports the efficacy observed with voclosporin in the Phase 3 AURORA and the prior Phase 2 AURA-LV global trials.
  • ||||||||||  Luveniq (voclosporin) / Aurinia Pharma, Otsuka
    [VIRTUAL] Efficacy of Voclosporin Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURORA and AURA-LV Trials () -  Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_569;    
    This analysis further supports the efficacy observed with voclosporin in the Phase 3 AURORA and the prior Phase 2 AURA-LV global trials. INTRODUCTION Voclosporin (VCS) is a novel calcineurin inhibitor with a favorable metabolic profile and a consistent dose-concentration relationship, potentially eliminating the need for drug level monitoring. Pooled data from the Phase 2 AURA-LV and the Phase 3 AURORA trials, which were similar in design, demonstrated that compared with mycophenolate mofetil (MMF) and steroids, the addition of VCS resulted in higher renal response rates (RR) at 24 weeks (31.7% vs 20.3%; OR 2.01; p=0.0008) and 1 year (43.7% vs 23.3%; OR 2.76; p1) across all biopsy classes, with the highest OR seen in pure Class III. This analysis further supports the efficacy observed with VCS in the AURORA and AURA-LV trials.
  • ||||||||||  Luveniq (voclosporin) / Aurinia Pharma
    Journal:  Differential effects of voclosporin and tacrolimus on insulin secretion from human islets. (Pubmed Central) -  Jan 30, 2021   
    RNA sequencing showed that TAC significantly decreased the expression of 17 genes, including direct and indirect regulators of exocytosis (SYT16, TBC1D30, PCK1, SMOC1, SYT5, PDK4, and CREM), whereas VCS has less broad and milder effects on gene expression. Clinically relevant doses of TAC, but not VCS, directly inhibit insulin secretion from human islets, likely via transcriptional control of exocytosis machinery.
  • ||||||||||  rifampicin / Generic mfg.
    Journal:  Orphan response regulator Rv3143 increases antibiotic sensitivity by regulating cell wall permeability in Mycobacterium smegmatis. (Pubmed Central) -  Nov 21, 2020   
    Transcriptome sequencing indicated that 198 potential genes were regulated by Rv3143, affecting the sensitivity of the strain to rifampicin (RIF)...Rv1524, the homologous gene of MSMEG_4740, belonging to the glycosyltransferase (Gtf) family, was related to cell wall modification...In addition, a combination of Rv3143 and RIF was observed. Our findings provide a new strategy for treating drug-resistant tuberculosis by increasing the expression of Rv3143 to enhance the strain sensitivity to antibiotics.
  • ||||||||||  Lupkynis (voclosporin) / Aurinia Pharma, Otsuka
    Enrollment closed:  AURORA2: Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin (clinicaltrials.gov) -  Aug 21, 2020   
    P3,  N=216, Active, not recruiting, 
    As changes in exposure to MPA may affect its efficacy and safety, these data confirm that VCS and MMF can be given concomitantly without the need to adjust MMF dose Recruiting --> Active, not recruiting